Complete clinical reference for the 2026 Surviving Sepsis Campaign international guidelines — 129 evidence-based recommendations covering screening, antimicrobial therapy, hemodynamic management, respiratory support, adjunctive therapies, goals of care, transitions, and long-term outcomes in adult sepsis and septic shock.
Surviving Sepsis Campaign 2026 recommendations for goals of care discussions, advanced directives, time-limited trials, palliative care, ICU transition programs, handoff processes, medication reconciliation, discharge planning, patient and family education, post-critical illness follow-up, physical rehabilitation, mental health support, and cognitive recovery in adult sepsis and septic shock.
Surviving Sepsis Campaign 2026 pediatric recommendations for immune stimulants in immunoparalysis, immunosuppressive therapy for hyperferritinemia, early rehabilitation bundles, targeted posthospital follow-up, post-sepsis morbidity screening, stress ulcer prophylaxis, VTE prophylaxis, nutrition, and blood products in children with sepsis.
Surviving Sepsis Campaign 2026 recommendations for blood pressure monitoring, fluid type selection, balanced crystalloids, albumin, liberal vs restrictive fluid strategies, dynamic measures for fluid responsiveness, cardiac output monitoring, serial lactate, capillary refill time, vasopressor hierarchy, inotropes, methylene blue, midodrine, and beta-blockers in adult sepsis and septic shock.
Evidence-based guideline for venous thromboembolism prevention in critically ill patients, including pharmacologic and mechanical prophylaxis, special populations, and monitoring.
Evidence-based guideline for VAP prevention bundles, diagnostic approaches, empiric and targeted antimicrobial therapy, and surveillance in mechanically ventilated patients.
Evidence-based guideline for classification, imaging decisions, ICP management, surgical indications, and outcome prediction in traumatic brain injury across all severity levels.
Evidence-based guideline for systematic trauma evaluation including ABCDE primary survey, hemorrhagic shock management, damage control resuscitation, injury-specific assessment, and special populations.
Evidence-based guideline for red cell, platelet, plasma, and cryoprecipitate transfusion, massive transfusion protocols, transfusion reactions, and patient blood management in the critically ill.
Evidence-based guideline for recognition, decontamination, specific antidote therapy, and enhanced elimination in acute poisoning and overdose presentations.
Evidence-based guideline for screening, resuscitation, hemodynamic management, antimicrobial therapy, and organ support in sepsis and septic shock, synthesized from international critical care recommendations.
Evidence-based guideline for pain assessment, sedation management, delirium prevention and treatment, early mobility, and sleep promotion in the ICU — the PADIS/ABCDEF bundle approach.
Evidence-based guideline for post-ROSC management, targeted temperature management, neuroprognostication, seizure management, and long-term recovery after cardiac arrest.
Evidence-based guideline for pediatric resuscitation, respiratory emergencies, sepsis, febrile infant evaluation, seizures, dehydration, and common surgical emergencies in children.
Evidence-based guideline for nutritional assessment, enteral and parenteral nutrition, micronutrient supplementation, and special population management in the critically ill patient.
Evidence-based guideline for lung-protective ventilation, prone positioning, PEEP optimization, rescue therapies, and ventilator liberation in acute respiratory distress syndrome.
Evidence-based clinical guidelines for infection prevention practice — guideline development methodology, CLABSI prevention, and infection control standards.
Comprehensive, evidence-based clinical guidelines for intensive care practice — synthesized from multiple professional society recommendations covering sepsis, ventilation, sedation, infection prevention, nutrition, hemostasis, renal support, post-arrest care, and transfusion medicine.
Comprehensive, evidence-based clinical guidelines for emergency medicine practice — cardiac emergencies, stroke, trauma, toxicology, airway management, pediatrics, and procedural care.
Comprehensive, evidence-based clinical guidelines for emergency medicine practice — synthesized from multiple professional society recommendations covering cardiac emergencies, stroke, trauma, toxicology, airway management, pediatrics, and procedural care.
Evidence-based guideline for CLABSI prevention, including insertion and maintenance bundles, supplemental strategies, diagnosis and management of catheter-related bloodstream infections, and surveillance.
Evidence-based guideline for recognition, evaluation, thrombolysis, thrombectomy, and management of ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage in the emergency department.
Evidence-based guideline for multimodal analgesia, opioid stewardship, ultrasound-guided regional anesthesia, and procedural sedation agents and protocols in the ED.
Evidence-based guideline for AKI staging, prevention, conservative management, renal replacement therapy modalities, CRRT prescription, and special populations in the critically ill.
Evidence-based guideline for evaluation and management of surgical and non-surgical abdominal emergencies including appendicitis, cholecystitis, pancreatitis, bowel obstruction, and mesenteric ischemia.
Sepsis management in immunocompromised patients, elderly, and pregnancy; bundle compliance and quality metrics; post-sepsis syndrome; long-term outcomes and performance improvement.
PADIS management in special populations including post-operative, neurological injury, substance withdrawal (alcohol/CIWA, opioid/COWS), ECMO and CRRT dosing adjustments, plus quality metrics, bundle compliance measurement, and implementation strategies.
Extracorporeal CPR indications and evidence, CPR quality metrics and physiologic targets, pediatric cardiac arrest differences with weight-based dosing, neonatal resuscitation overview, termination of resuscitation criteria, and post-arrest care cross-reference.
VTE prophylaxis in traumatic brain injury, spinal cord injury, neurosurgery, burns, stroke, cardiac surgery, orthopedic trauma, ECMO, thrombocytopenia, active bleeding, pregnancy, and obesity; HIT recognition and alternative anticoagulants; quality metrics and compliance monitoring.
Pathogen-directed therapy for MRSA, Pseudomonas aeruginosa, Acinetobacter baumannii, ESBL-producing Enterobacterales, and Stenotrophomonas maltophilia with dosing tables, VAE versus traditional VAP surveillance reporting, NHSN definitions and algorithms, quality metrics including VAE rates and bundle compliance, and antibiotic stewardship considerations.
Recognition and management of all transfusion reactions (hemolytic, FNHTR, allergic, TRALI, TACO), TRALI vs TACO differential table, reporting requirements, patient blood management (PBM), special populations including Jehovah's Witness patients, and quality metrics.
Complete management of methanol and ethylene glycol poisoning (fomepizole, hemodialysis), carbon monoxide, cyanide, organophosphates and nerve agents, iron poisoning, caustic ingestions, local anesthetic systemic toxicity (LAST), sympathomimetic toxicity, and enhanced elimination techniques including urinary alkalinization and EXTRIP hemodialysis indications.
Continuous EEG monitoring, seizure and status epilepticus treatment, organ donation considerations, cardiac rehabilitation, ICD evaluation, cognitive recovery, and quality metrics after cardiac arrest.
Febrile seizure evaluation, status epilepticus protocol with stepwise treatment, clinical dehydration assessment, WHO dehydration classification, ORT protocol, IV fluid calculation with Holliday-Segar rule, hyponatremia correction, and pediatric diabetic ketoacidosis management including 2-bag system and cerebral edema monitoring.
Safety screening criteria for ICU mobilization, progressive mobility levels, ICU-acquired weakness diagnosis and prevention, barriers to early mobility, sleep disruption assessment and causes, non-pharmacologic and pharmacologic sleep interventions, and circadian rhythm management.
Comprehensive guide to immunonutrition (arginine, glutamine, omega-3 fatty acids, antioxidants), and nutrition management in special ICU populations including sepsis, burns, trauma, TBI, acute pancreatitis, ECMO, obesity, chronic critical illness, open abdomen, and CRRT.
Early invasive vs conservative strategy, timing of angiography, antiplatelet and anticoagulation for NSTEMI, special populations (women, elderly, diabetes, CKD, cocaine), arrhythmias, and chest pain disposition.
Scenario-specific airway management for trauma, elevated ICP, status asthmaticus, morbid obesity, pregnancy, pediatric patients, angioedema/anaphylaxis, and burns. Complete post-intubation ventilator settings, sedation/analgesia regimens, extubation criteria, and equipment reference tables by age and weight.
Comprehensive guide to perforated peptic ulcer with Boey score, mesenteric ischemia types and management, ruptured AAA emergency management, ectopic pregnancy evaluation and treatment, and special populations including pediatric, elderly, immunocompromised, and pregnant patients.
Evidence for intermittent pneumatic compression and graduated compression stockings, IVC filter indications and complications, screening ultrasound protocols, CTPA decision-making, and transition from prophylaxis to treatment.
Massive transfusion protocol activation, fixed-ratio transfusion (1:1:1 per PROPPR), TEG/ROTEM viscoelastic testing and interpretation, damage control resuscitation, TXA (CRASH-2), calcium replacement, permissive hypotension, and hemorrhage management in trauma, obstetric, and GI bleeding.
Timing of antibiotics, empiric broad-spectrum regimens by suspected source, de-escalation, duration of therapy, procalcitonin-guided discontinuation, antifungal considerations, and source control procedures.
Antimicrobial-impregnated catheters, antimicrobial lock therapy, CHG-impregnated dressings, antibiotic ointments, diagnosis of CRBSI (paired blood cultures, differential time to positivity, catheter tip culture), empiric therapy, catheter removal vs salvage, duration of therapy by organism, and suppurative thrombophlebitis.
Recruitment maneuvers and evidence from the ART trial, conservative fluid management from the FACTT trial, inhaled pulmonary vasodilators, ECMO indications and referral criteria from the EOLIA trial, high-frequency oscillatory ventilation, and corticosteroids in ARDS.
Comprehensive guide to parenteral nutrition in the ICU: indications, timing controversies, composition, lipid emulsions, monitoring, complications, transition to EN, and micronutrient supplementation including thiamine, vitamin C, vitamin D, selenium, zinc, and refeeding syndrome prevention.
Fluid management, hyperkalemia emergency algorithm, electrolyte and acid-base management, diuretic therapy including furosemide stress test, drug dosing in AKI, and nutritional considerations.
Systems of care, primary PCI, fibrinolytic therapy with dosing, pharmacoinvasive strategy, dual antiplatelet therapy, anticoagulation, adjunctive therapy, cardiogenic shock, and mechanical complications.
Failed first attempt optimization, video laryngoscopy types and evidence, bougie technique, supraglottic airways with sizing tables, intubating through SGA, front-of-neck access (FONA), surgical cricothyrotomy (scalpel-bougie-tube), needle cricothyrotomy, and the complete difficult airway algorithm.
Comprehensive guide to adhesive small bowel obstruction with CT findings, conservative management, water-soluble contrast challenge, and surgical indications; large bowel obstruction including volvulus and Ogilvie syndrome; and diverticulitis with Hinchey classification, DIABOLO trial evidence, and surgical decision-making.
Complete dosing tables for LMWH, UFH, and fondaparinux in ICU patients, renal and obesity dose adjustments, anti-Xa monitoring, key trial evidence (PROTECT, PREVENT, INSPIRATION), and duration of prophylaxis.
Comprehensive evidence review of VAP prevention bundle components including head-of-bed elevation, sedation management, oral care and chlorhexidine controversy, subglottic secretion drainage, ETT cuff pressure, suctioning, circuit management, early mobility, stress ulcer prophylaxis, and supplemental strategies including SDD/SOD, silver-coated ETTs, and probiotics.
Extended FAST technique, chest and pelvis radiography, Foley and NG tube placement, complete head-to-toe secondary survey, AMPLE history, and hemorrhagic shock classification with Classes I-IV.
Evidence-based indications, thresholds, and dosing for platelet, plasma (FFP/FP24), and cryoprecipitate/fibrinogen concentrate transfusion, including platelet refractoriness, warfarin reversal, and special considerations for HIT, TTP, ITP, and DIC.
Complete TTM protocol including historical evolution, landmark trial evidence, temperature targets, cooling methods, shivering management, complications, and special populations.
Croup scoring and management, bronchiolitis evaluation and supportive care, acute asthma severity classification and stepwise treatment, anaphylaxis recognition and epinephrine dosing, and foreign body aspiration management.
Indications, protocols, and evidence for prone positioning in ARDS based on the PROSEVA trial, procedural checklists and contraindications, neuromuscular blockade evidence from ACURASYS and ROSE trials, train-of-four monitoring, and current recommendations.
Comprehensive guide to enteral nutrition in the critically ill: timing of initiation, gastric vs post-pyloric access, advancement protocols, formula selection, gastric residual volume management, prokinetic agents, complications including aspiration and refeeding syndrome, and EN during prone positioning and vasopressor therapy.
Pre-renal, intrinsic, and post-renal AKI causes; diagnostic workup including urinalysis, FENa, FEUrea, and imaging; prevention strategies; nephrotoxin avoidance; contrast-associated AKI evidence; drug dose adjustment table.
Complete RSI protocol including preparation, pretreatment agents, induction agents with dosing tables, neuromuscular blocking agents with contraindications and reversal, paralysis verification, post-intubation sedation, confirmation of intubation, awake intubation, and drug-assisted intubation without paralysis.
Comprehensive guide to acute cholecystitis with Tokyo Guidelines severity grading, cholangitis management, ERCP indications, and acute pancreatitis with Revised Atlanta Classification, BISAP score, Ranson criteria, CTSI/Balthazar score, fluid resuscitation, nutrition, and necrotizing pancreatitis management.
Incidence and pathophysiology of VTE in critically ill patients, comprehensive ICU risk factors, and complete risk assessment scoring systems including Padua Prediction Score, Caprini Score, and IMPROVE Score.
Clinical and surveillance definitions of VAP, the VAE tier system (VAC, IVAC, PVAP), HAP versus VAP distinction, epidemiology including incidence and mortality data, pathogenesis of aspiration and biofilm formation, and modifiable and non-modifiable risk factors.
GCS scoring, TBI severity classification, Canadian CT Head Rule, New Orleans Criteria, PECARN pediatric head CT algorithm, and comparison of imaging decision rules with sensitivity and specificity data.
Two-tier trauma team activation criteria, CDC field triage, and complete ABCDE primary survey including airway with C-spine protection, breathing and ventilation, circulation with hemorrhage control, disability assessment with GCS, and exposure/environment.
Initial approach to the poisoned patient including toxidrome recognition, diagnostic workup, toxicology screen interpretation, and gastrointestinal decontamination strategies including activated charcoal, whole bowel irrigation, gastric lavage, and multi-dose activated charcoal.
Sepsis-3 definitions, SOFA and qSOFA scoring, septic shock criteria, comparison with SIRS/Sepsis-2, and screening tools (NEWS, MEWS, qSOFA, SIRS) with sensitivity and specificity data.
Pathophysiology of post-cardiac arrest syndrome, airway and ventilation targets, hemodynamic optimization, coronary angiography indications, and initial workup after ROSC.
The ABCDEF bundle framework for ICU liberation, comprehensive pain assessment tools (BPS, CPOT, NRS) with complete scoring tables, and evidence-based analgesic management including opioid dosing, non-opioid adjuncts, and multimodal protocols.
Comprehensive guide to nutrition screening tools (NUTRIC score, NRS-2002, mNUTRIC), limitations of traditional biomarkers, body composition assessment, indirect calorimetry, predictive equations, caloric and protein targets, and obesity adjustments in the critically ill adult.
Pain assessment scales (NRS, VAS, FACES, FLACC, PAINAD), oligoanalgesia prevention, and first-line non-opioid analgesics including acetaminophen, NSAIDs, subdissociative ketamine, IV lidocaine, trigger point injections, and nitrous oxide.
KDIGO AKI definition and staging criteria, RIFLE and AKIN historical comparison, novel biomarkers (NGAL, KIM-1, NephroCheck), subclinical AKI, ICU epidemiology, and outcomes by stage.
ACS spectrum definitions, Fourth Universal Definition of MI (Types 1-5), pathophysiology, initial ED evaluation, 12-lead ECG interpretation, STEMI criteria by territory, STEMI equivalents, and right ventricular MI.
Structured approach to acute abdominal pain evaluation including history, physical exam, differential diagnosis by pain location, laboratory and imaging strategy, and comprehensive appendicitis management with Alvarado score, AIR score, and CODA trial evidence.
Evidence-based guideline for the safe handling, preparation, administration, and disposal of hazardous drugs in healthcare settings, including engineering controls, PPE, and exposure management.
Evidence-based guideline for prevention, assessment, and management of oral and GI mucositis in cancer patients receiving chemotherapy, radiation, and stem cell transplantation.
Evidence-based guideline for surveillance, late effects monitoring, health promotion, and comprehensive survivorship care planning for cancer survivors.
Comprehensive, evidence-based clinical guidelines for oncology practice — synthesized from multiple professional society recommendations covering vascular access, supportive care, safety, pain management, immunotherapy, and survivorship.
Comprehensive, evidence-based clinical guidelines for oncology practice — vascular access, supportive care, safety, pain management, immunotherapy, and survivorship.
Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.
Evidence-based guideline for prevention, recognition, and management of chemotherapy extravasation injuries, including agent classification, antidote protocols, and follow-up care.
Evidence-based guideline for selection, insertion, maintenance, and complication management of central venous access devices in oncology patients, synthesized from multiple professional society recommendations.
Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
Pediatric oncology, elderly patients, thrombocytopenic and anticoagulated patients, device removal criteria and procedures, patient and caregiver education, and quality surveillance for CVADs in oncology.
Risk-stratified survivorship care models, shared care integration, transition from oncology to primary care, pediatric and AYA survivorship, childhood cancer late effects, financial toxicity, and psychosocial support resources.
Medical surveillance program design and components, biological monitoring, reproductive health counseling and alternative duty policies, training and competency assessment requirements, documentation and record-keeping, non-antineoplastic hazardous drug considerations, home administration guidance, and quality assurance.
Depression, anxiety, PTSD, fear of recurrence, sexual health, physical activity, nutrition, smoking cessation, alcohol, sun protection, and immunizations for cancer survivors.
Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia, central line-associated bloodstream infections in neutropenic patients, infection prevention measures, and patient and caregiver education.
Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.
Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.
Adjuvant analgesic dosing for neuropathic and bone pain, interventional pain procedures, palliative radiation, and chemotherapy-induced peripheral neuropathy prevention and treatment.
Spill classification and step-by-step response procedures, spill kit contents, personnel exposure management during spills, hazardous drug waste segregation and disposal, and surface decontamination protocols including deactivation, decontamination, and cleaning agents.
Flushing and locking protocols, dressing change procedures, needleless connector management, port access and deaccess procedures, blood sampling, and patency assessment for CVADs in oncology patients.
Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.
Fluoroquinolone prophylaxis, antifungal prophylaxis, antiviral and PJP prophylaxis, G-CSF primary and secondary prophylaxis with dosing and timing, therapeutic G-CSF in established febrile neutropenia, and management of persistent fever and documented infections.
Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.
Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.
Complete opioid pharmacotherapy for cancer pain including equianalgesic dosing, titration protocols, opioid rotation, breakthrough pain management, methadone pharmacology, and side effect treatment.
Complete PPE specifications for hazardous drug handling by activity type, including glove, gown, eye/face, and respiratory protection requirements; detailed procedures for receiving, storage, compounding, administration, patient care, and transport.
Insertion site selection, ultrasound-guided placement, tip confirmation, skin antisepsis, dressing and securement, and site care protocols for central venous access devices in oncology patients.
Anthracycline cardiomyopathy, radiation-associated cardiovascular disease, cardiac monitoring protocols, cardioprotective strategies, and screening for secondary malignancies in cancer survivors.
Empiric intravenous antibiotic monotherapy and combination regimens with complete dosing, indications for vancomycin and anti-gram-positive agents, antibiotic de-escalation and duration criteria, outpatient eligibility for low-risk febrile neutropenia, oral antibiotic regimens, and monitoring requirements.
Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.
Signs and symptoms of extravasation (early and late), differential diagnosis, step-by-step immediate management algorithm, specific antidote protocols with complete dosing for dexrazoxane, hyaluronidase, sodium thiosulfate, and DMSO, and thermal management by agent class.
Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.
Hazardous drug definitions, NIOSH classification criteria, national drug list organization, exposure routes and health effects, facility risk assessment, and complete engineering control specifications including BSCs, CACIs, CSTDs, and ventilation requirements.
CVAD types and oncology-specific indications, patient assessment framework, vein selection in cancer patients, device selection algorithms, and special population considerations for central venous access in oncology.
Survivorship care plan components, structure, and evidence-based surveillance schedules for recurrence monitoring in breast, colorectal, prostate, lung, lymphoma, and head and neck cancer survivors.
Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.
Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.
Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.
Comprehensive pain assessment tools, classification systems, and cancer-specific pain syndromes for systematic evaluation of pain in oncology patients.
Association for Vascular Access (AVA) Adult Clinical Practice Guidelines — JAVA January Supplement 2026, Volume 31. Evidence-based recommendations for vascular access practice.
Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 5: Comprehensive glossary of vascular access terminology and definitions referenced throughout the guidelines.
Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 4 covering Sections 5–6: Device Maintenance, Complication Identification & Management, and Special Patient Populations.
Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 3 covering Sections 3–4: Vascular Access Device Selection, Site Selection, and Insertion Techniques including ultrasound guidance.
Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 2 continuing Section 1 on implementation considerations, barriers, products, bundles, and checklists for vascular access infrastructure.
A comprehensive methodology handbook for developing clinical guidelines, expert guidance documents, consensus statements, and practice statements in infection prevention and healthcare epidemiology. Covers proposal processes, systematic literature review, evidence grading, consensus methods, and development timelines.
Development checklists (32-month, 22-month, and 6-month timelines), review and comment period procedures, writing panel author responsibilities, inclusive language guide, and acronyms for infection prevention guideline development.